GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology market and expanding its preventive healthcare through adult vaccines. With 30 crore prescriptions annually, GSK aims to innovate and grow its portfolio, highlighting price strategies catering to a broad market range, from general medicines to high-value therapies.
Related Posts
Goldman Sachs: India needs to create 10 million jobs/year
Goldman Sachs estimates India needs to create 10 million jobs annually to sustain 6.5% GVA growth. Key policy recommendations include incentivizing affordable social housing, diversifying […]
Who is Sagar Adani, accused of bribery and fraud charges along with Gautam Adani in the US?
US prosecutors have accused Sagar Adani, nephew of Indian billionaire Gautam Adani, and others of orchestrating a massive bribery scheme. They allegedly paid over $250 […]
Vishal Mega Mart set to debut in Mumbai after $944 million IPO
Vishal Mega Mart Ltd. launched its IPO, raising $944 million and valuing the company at $4 billion. The offering was oversubscribed 27 times, driven by […]